GlassScriptPhysician profile
Manikanda G Raja
NPI 1730290321
$15,337.89
in general payments reported to CMS, 2019-2025
66 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $2,807 · 2021: $3,312 · 2022: $2,578 · 2023: $1,743 · 2024: $1,110 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,676.91 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $1,339.17 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $951.48 | 2019-2024 | Xarelto |
| Amgen INC. | $914.31 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $902.83 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $884.50 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $749.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $725.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $659.99 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $496.86 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $428.49 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $393.54 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $388.71 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $384.45 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $383.69 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manikanda Raja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.